Endometrial Cancer, First-line treatment, Chemotherapy, Avelumab
Ovarian Neoplasms, Immune checkpoint inhibitors, atezolizumab [Supplementary Concept], CA-125 antigen, Prognosis
Placebo, adverse events, trial design, ovarian cancer, maintenance therapy, PARPi